BlackRock
ALDX icon

BlackRock’s Aldeyra Therapeutics ALDX Stock Holding History

BlackRock’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.68M Sell
1,257,243
-2,506,644
-67% -$4.31M ﹤0.01% 4085
2026
Q1 		$6.36M Sell
3,763,887
-86,216
-2% -$378K ﹤0.01% 3733
2025
Q4 		$19.9M Buy
3,850,103
+45,183
+1% +$232K ﹤0.01% 3113
2025
Q3 		$19.9M Sell
3,804,920
-47,181
-1% -$246K ﹤0.01% 3090
2025
Q2 		$14.8M Buy
3,852,101
+116,063
+3% +$300K ﹤0.01% 3198
2025
Q1 		$21.5M Sell
3,736,038
-54,152
-1% -$320K ﹤0.01% 2888
2024
Q4 		$18.9M Buy
3,790,190
+55,782
+1% +$286K ﹤0.01% 3087
2024
Q3 		$20.1M Buy
3,734,408
+112,459
+3% +$535K ﹤0.01% 3040
2024
Q2 		$12M Buy
3,621,949
+311,162
+9% +$1.22M ﹤0.01% 3277
2024
Q1 		$10.8M Sell
3,310,787
-119,987
-3% -$395K ﹤0.01% 3311
2023
Q4 		$12M Buy
3,430,774
+59,642
+2% +$184K ﹤0.01% 3294
2023
Q3 		$22.5M Buy
3,371,132
+140,718
+4% +$1.04M ﹤0.01% 2875
2023
Q2 		$27.1M Buy
3,230,414
+2,245,432
+228% +$22.1M ﹤0.01% 2846
2023
Q1 		$9.78M Buy
984,982
+12,546
+1% +$88.7K ﹤0.01% 3335
2022
Q4 		$6.77M Buy
972,436
+2,350
+0.2% +$13.4K ﹤0.01% 3572
2022
Q3 		$5.18M Sell
970,086
-4,861
-0.5% -$29.2K ﹤0.01% 3741
2022
Q2 		$3.89M Sell
974,947
-2,245,564
-70% -$7.72M ﹤0.01% 3938
2022
Q1 		$14.3M Sell
3,220,511
-8,300
-0.3% -$33.1K ﹤0.01% 3380
2021
Q4 		$12.9M Sell
3,228,811
-35,131
-1% -$268K ﹤0.01% 3521
2021
Q3 		$28.7M Sell
3,263,942
-11,842
-0.4% -$109K ﹤0.01% 3046
2021
Q2 		$37.1M Buy
3,275,784
+2,222,456
+211% +$26.7M ﹤0.01% 2890
2021
Q1 		$12.5M Buy
1,053,328
+273,024
+35% +$3.14M ﹤0.01% 3450
2020
Q4 		$5.35M Buy
780,304
+29,160
+4% +$205K ﹤0.01% 3680
2020
Q3 		$5.57M Buy
751,144
+267,571
+55% +$1.73M ﹤0.01% 3527
2020
Q2 		$2.02M Sell
483,573
-1,130,619
-70% -$4.13M ﹤0.01% 3822
2020
Q1 		$3.99M Buy
1,614,192
+29,567
+2% +$133K ﹤0.01% 3445
2019
Q4 		$9.21M Sell
1,584,625
-1,478
-0.1% -$8.54K ﹤0.01% 3286
2019
Q3 		$8.36M Buy
1,586,103
+47,637
+3% +$256K ﹤0.01% 3297
2019
Q2 		$9.23M Buy
1,538,466
+196,463
+15% +$1.48M ﹤0.01% 3289
2019
Q1 		$12.1M Buy
1,342,003
+43,288
+3% +$368K ﹤0.01% 3020
2018
Q4 		$10.8M Buy
1,298,715
+501,927
+63% +$5.14M ﹤0.01% 3048
2018
Q3 		$11M Buy
796,788
+16,044
+2% +$130K ﹤0.01% 3191
2018
Q2 		$6.21M Buy
780,744
+741,337
+1,881% +$5.91M ﹤0.01% 3446
2018
Q1 		$296K Buy
39,407
+1,713
+5% +$13K ﹤0.01% 4135
2017
Q4 		$256K Buy
37,694
+27
+0.1% +$178 ﹤0.01% 4168
2017
Q3 		$271K Sell
37,667
-1,877
-5% -$9.8K ﹤0.01% 4168
2017
Q2 		$184K Buy
39,544
+4,449
+13% +$20.5K ﹤0.01% 4268
2017
Q1 		$175K Buy
+35,095
New +$181K ﹤0.01% 4243

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BlackRock's ALDX Position: Q2 2026 in Review

BlackRock reduced its Aldeyra Therapeutics (ALDX) stake by 67% in Q2 2026, selling an estimated $4.31M and leaving 1,257,243 shares worth $2.68M. The position accounts for ﹤0.01% of the portfolio, ranked #4085.

BlackRock first reported a position in ALDX in Q1 2017 and has held it in 38 quarters since. The position peaked at $37.1M in Q2 2021. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • BlackRock held 1,257,243 shares of Aldeyra Therapeutics worth $2.68M as of Q2 2026.
  • BlackRock sold 2,506,644 Aldeyra Therapeutics shares in Q2 2026, an estimated $4.31M.
  • Aldeyra Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4085 holding.
  • BlackRock first reported a position in Aldeyra Therapeutics in Q1 2017 and has held it in 38 quarters since.
  • BlackRock's Aldeyra Therapeutics position peaked at $37.1M in Q2 2021.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.